B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on NGM Biopharmaceuticals (NASDAQ:NGM) Inc on Thursday, setting a price target of $25, which is approximately 26.77% above the present share price of $19.72.
Mamtani expects NGM Biopharmaceuticals Inc to post earnings per share (EPS) of -$0.36 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in NGM Biopharmaceuticals, with an average price target of $25.67.
The analysts price targets range from a high of $44 to a low of $20.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $21.58 million and a net profit of -$27.85 million. The company's market cap is $1.52 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 26.7% and a 54.87% success rate.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.